Ganga Pharmaceuticals Limited (BOM:539680)
India · Delayed Price · Currency is INR 12.00
0.00 (0.00%)
At close: Feb 12, 2026
Ganga Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 0.58 | 3.02 | 0.3 | 0.29 | 0.2 |
Cash & Short-Term Investments | 0.58 | 3.02 | 0.3 | 0.29 | 0.2 |
Cash Growth | -80.75% | 913.76% | 2.86% | 41.85% | 40.88% |
Accounts Receivable | 9.39 | 9.11 | 9.23 | 8.89 | 8.92 |
Receivables | 38.64 | 35.23 | 25.13 | 24.01 | 25.47 |
Inventory | 11.65 | 11.82 | 12.41 | 11.83 | 11.5 |
Other Current Assets | 24.77 | 18.6 | 19.66 | 15.35 | 11.91 |
Total Current Assets | 75.65 | 68.67 | 57.5 | 51.47 | 49.08 |
Property, Plant & Equipment | 6.46 | 6.65 | 6.12 | 6.39 | 6.81 |
Long-Term Investments | - | - | 8.44 | 0.85 | 0.85 |
Other Long-Term Assets | 14.39 | 14.41 | 14.41 | 21.12 | 23.21 |
Total Assets | 96.49 | 89.72 | 86.48 | 79.84 | 79.95 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 1.18 | 2.78 | 1 | 5.81 | 5.26 |
Accrued Expenses | - | 0.7 | 0.66 | 0.51 | 0.59 |
Short-Term Debt | 9.92 | 10.14 | 7.57 | 10.28 | 9.2 |
Current Portion of Long-Term Debt | - | 1.75 | 2.06 | 1.64 | 1.16 |
Current Income Taxes Payable | 0.3 | 0.15 | 0.16 | 0.16 | 0.14 |
Other Current Liabilities | 0.95 | 0.52 | 0.5 | 0.55 | 0.52 |
Total Current Liabilities | 12.35 | 16.03 | 11.95 | 18.95 | 16.86 |
Long-Term Debt | 0.98 | 2.32 | 3.95 | 6.35 | 8.92 |
Long-Term Deferred Tax Liabilities | 0.03 | 0.06 | 0.05 | 0.05 | 0.07 |
Other Long-Term Liabilities | - | -0 | 0 | - | - |
Total Liabilities | 13.37 | 18.41 | 15.95 | 25.34 | 25.84 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 59.12 | 48.37 | 48.37 | 40.62 | 40.62 |
Additional Paid-In Capital | - | 7.68 | 7.68 | 6.08 | 6.08 |
Retained Earnings | - | 9.06 | 8.27 | 7.81 | 7.41 |
Comprehensive Income & Other | 24.01 | 6.21 | 6.21 | - | - |
Shareholders' Equity | 83.13 | 71.31 | 70.53 | 54.5 | 54.11 |
Total Liabilities & Equity | 96.49 | 89.72 | 86.48 | 79.84 | 79.95 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 10.9 | 14.21 | 13.58 | 18.26 | 19.28 |
Net Cash (Debt) | -10.32 | -11.19 | -13.28 | -17.97 | -19.07 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -1.73 | -1.69 | -2.01 | -4.43 | -4.70 |
Filing Date Shares Outstanding | 5.74 | 4.84 | 4.84 | 4.06 | 4.06 |
Total Common Shares Outstanding | 5.74 | 4.84 | 4.84 | 4.06 | 4.06 |
Working Capital | 63.29 | 52.64 | 45.55 | 32.53 | 32.22 |
Book Value Per Share | 14.48 | 14.74 | 14.58 | 13.42 | 13.32 |
Tangible Book Value | 83.13 | 71.31 | 70.53 | 54.5 | 54.11 |
Tangible Book Value Per Share | 14.48 | 14.74 | 14.58 | 13.42 | 13.32 |
Land | - | 2.27 | 2.27 | 2.27 | 2.27 |
Buildings | - | 2.28 | 2.28 | 2.28 | 2.28 |
Machinery | - | 10.13 | 9.14 | 8.92 | 8.77 |